Personalized Medicine – StemCell Therapy

NHS England Personalised medicine

♫ Wednesday, October 9th, 2019

Personalised medicine is a move away from a one size fits all approach to the treatment and care of patients with a particular condition, to one which uses new approaches to better manage patients health and targets therapies to achieve the best outcomes in the management of a patients disease or predisposition to disease.

We are all unique. Our health is determined by our inherent differences combined with our lifestyles and environment. By combining and analysing information about our genome, with other clinical and diagnostic information, patterns can be identified that can help to determine our individual risk of developing disease; detect illness earlier; and, determine the most effective interventions to help improve our health, be they medicines, lifestyle choices, or even simple changes in diet.

The concept of personalised medicine is not new. Clinicians have been working to personalise care, tailored to peoples individual health needs, throughout the history of medicine, but never before has it been possible to predict how each of our bodies will respond to specific interventions, or identify which of us is at risk of developing an illness. New possibilities are now emerging as we bring together novel approaches, such as whole genome sequencing, data and informatics, and wearable technology. It is the interconnections between these innovations that makes it possible to move to an era of truly personalised care.

Technological and scientific advances are already here and will continue to develop and improve medical practice; change is inevitable. For the NHS, we must consider not whether we should go down this path of personalised medicine, but instead how we can best respond and adapt, to ensure everyone benefits regardless of where people live, the illnesses they have, or where their care is provided.

We are on a journey towards embedding a personalised medicine approach into mainstream healthcare. NHS England is beginning a discussion about what we mean by personalised medicine, now and in the future, and the approach we will take, working with our partners, so that we can embrace new approaches, while ensuring that ethical, equality and economic implications are fully understood and addressed.

Through the 100,000 Genomes Project, a ground breaking and world leading initiative, the NHS is building partnerships with academia and industry to decode the human genome, in people with rare diseases and cancer. This will help to predict the future development of disease, to make a diagnosis where one has not existed previously and to identify treatments where possible. Please see the genomics page for further information.

Improving Outcomes through Personalised Medicine

If you have any queries regarding any aspect of personalised medicine please contact the Genomics Team at NHS England via:england.genomics@nhs.net

See the original post:
NHS England Personalised medicine

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine Market Size & Forecast | Industry …

♫ Wednesday, October 9th, 2019

Industry Insights

The global personalized medicine (PM) market size was estimated at USD 1.57 trillion in 2018 and is anticipated to expand at a CAGR of 10.6% during the forecast period. Personalized medicine promises a paradigm shift in diagnosis and care delivery as the treatment is based on data leveraged from a holistic view of an individual patient. Proliferation of sequencing methodologies, especially Next Generation Sequencing (NGS), due to rising cost of sequencing and development of Human Genome Project in genomics field is expected to drive the market.

NGS technology delivers the data related to the genetic makeup of the patient and response of drugs on patient, thereby fostering the development of precision medicineto treat diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is expected to play a major role for advancement of personalized diagnostics and therapeutics over the forthcoming years. Advent of novel CDx and biomarkers for non-oncology therapeutic applications have forced companies to improve their precision medicine portfolio; focusing oninfectious diseases and Cardiovascular Diseases (CVDs).

This generates a strong impetus for scaling up the CDx tests to form PM for non-oncology cases. Increasing prevalence of cancer, which boosts demand for personalized cancer diagnostics and therapeutics, is also one of the key factors responsible for the growth of the market. As per data GLOBOCAN 2018, the global burden of cancer has increased to 18.1 million new cases in 2018. Growing cancer-related spending is also amongst the drivers for growth.

Key companies in the personalized medicine market are involved in several investment programs pertaining to the precision medicine. This has resulted in an increased commitment of leading pharma competitors toward this sector. Furthermore, companies providing molecular decision support system are combining genomic data with clinical data to minimize the gaps in precision medicine practice.

Personalized nutrition & wellness was the largest product segment in 2018. Availability of a wide range of nutrition & wellness products and increased Over The Counter (OTC) sale of these productsplay a significant role in boosting the segment growth. Companies are undertaking several initiatives for sustaining market competition. For instance, in March 2018, DSM partnered with Mixfit to provide personalized nutrition solutions by combining Artificial Intelligence (AI) technology.

This strategic partnership was targeted towards offering consumers a personalized approach regarding nutrition. PM therapeutics includes pharmaceuticals, genomic medicine, and medical devices for personalized therapies and it is anticipated to witness the highest CAGR during the forecast period. Advent of high-capacity rapid sequencing platforms and reducing cost of sequencing whole human genome plays a major role in the segment development.

Genomic medicine has emerged as a significant segment in PM therapeutics. Availability of large databases of genomic data enables researchers to develop accurate and effective therapeutic products for several medical conditions. Consequently, this results in high utilization of human genome sequencing techniques for genomic medicine.

Led by U.S., North America was the dominant regional personalized medicine market in 2018. Increasing adoption of NGS methods and healthcare IT systems in clinical workflow along with supportive government policies and funding drives the regional market.

For instance, in September 2018, the All of Us Research Program initiated by the National Institutes of Health (NIH) awarded funds of USD 28.6 million to three genome centers of the U.S. This funding supported the generation of genomic data from biosamples by these centers, which is a critical component of precision medicine discoveries.

However, Asia Pacific is projected to witness the highest CAGR over the forecast period owing to low cost of clinical trialsof newly developed precision medicines and diagnostic products. Moreover, rising disposable income levels and growing economy of emerging countries will boost the market further.

Some key companies in this market include GE Healthcare; Illumina, Inc.; Asuragen, Inc.; Abbott Laboratories; Dako A/S; Exact Science Corporation; Danaher Corporation (Cepheid, Inc.);Decode Genetics, Inc.;Genelex Corporation; Exagen Diagnostics, Inc.; Precision Biologics, Inc.; QIAGEN; Celera Diagnostics LLC; and Biogen, Inc.

These companies invest in personalized products-focused innovations and developments for business expansion. For instance, in April 2018, Ilumina helped various startup companies by offering them financial support. One of such startups, TruGenomix Health, Inc. focused on individualized treatment options, thereby advancing personalized therapies.

Attribute

Details

Base year for estimation

2018

Actual estimates/Historical data

2014 - 2017

Forecast period

2019 - 2025

Market representation

Revenue in USD Million and CAGR from 2019 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, and MEA

Country scope

U.S., Canada, Germany, U.K., Japan, China, Brazil, and South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you are looking for specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global personalized medicine (PM) market report on the basis of product and region:

Product Outlook (Revenue, USD Million, 2014 - 2025)

Regional Outlook (Revenue, USD Million, 2014 - 2025)

Continued here:
Personalized Medicine Market Size & Forecast | Industry ...

♫ Posted in Personalized Medicine | | Comments Off»

Moving from Population Medicine to Personalized Medicine

♫ Wednesday, October 9th, 2019

In the United States, despite high hopes, our health-care system still generally operates as a one-size-fits-all model. Some refer to this as a population model. This paradigm suggests that in the majority of people, an ailmentbe it a common cold or cancerhas a common predicted trajectory, and most people will benefit from a homogeneous course of treatment. If a particular treatment does not work, then the second-most likely successful treatment plan is prescribed.

This continues until the ailment is relieved. Treatments are set based on available population statistics, and trial and error is used until the patient is well. In this model of medicine, personal characteristics, risk factors, lifestyle choices and genetics are rarely considered. Therefore, the treatment approach will not be ideal in all cases, failing those who do not fit with average parameters.

Personalized medicine, on the other hand, advocates the customization of health care. It aims to prevent diseases, as well as tailor treatments to an individual so a disease or illness can be targeted in a way that promises the highest chance of success based on the attributes of the individual. An underlying assumption of this approach is personalized medicine (PM) takes into account that drugs and interventions will have varying efficacy based on the person being treated.

Now that science possesses a complete map of all the genes in the body, personalized medicine is manifesting as a reality.

Angelina Jolies public disclosure about carrying a BRCA1 gene mutation, which puts her at high risk of breast cancer and ovarian cancer, brought some of these concepts to the publics attention. Making choices based on gene type might not yet be the norm in everyday health-care practice, but it is becoming more prevalent.

Oncology is an area of medicine where DNA sequencing technology has a lot of potential. For example, for lung cancer, there are many personalized treatment options now available based on different lung cancer biomarkers. If there is a medical indication, genetic tests can often be covered by insurance, especially if there is an FDA-approved drug or treatment that is tied to a genetic mutation.

Recently, researchers have also used DNA sequencing to establish the connection between bovine leukemia virus (BLV) and breast cancer. It was previously believed that this cattle virus cannot infect humans. However, a study conducted by the University of California, Berkeley, and the University of New South Wales, Sydney, showed that BLV can be present in human tissue three to 10 years before cancer gets diagnosed, indicating a strong correlation.

Genome-driven medical care is becoming increasingly utilized due to the development of next-generation sequencing (NGS) technologies.

According to The National Human Genome Research Institute, whole genome sequencing can now be performed in less than 24 hours for under $1,000. The genetic services have become more accurate and affordable and are now used in both public and private institutions. However, numerous challenges still need to be tackled. For instance, many doctors may lack training opportunities and are unfamiliar with the emerging technologies. Some experts also warn that there needs to be a balance between hope and hype and that ethical issues should be strictly monitored.

Perhaps one of the most sensational innovations in the area of personalized medicine is printing 3-D organs from ones own cells. It is predicted that in about 10 to 15 years, organs will routinely be produced from cells harvested from patients themselves using 3-D bioprinting technology. In the future, organ transplantations might eventually be replaced by customized organ-growing.

Anthony Atala, M.D., the Director of the Wake Forest Institute for Regenerative Medicine (WFIRM), has already demonstrated that transplantable kidneys can be produced using such a technique, helping to curb a crisis resulting from organ shortage. Currently, scientists at WFIRM are engineering over 30 different tissues and organs that could be used as replacement organs. Organovo, a company working on personalized bioprinted human tissue, has so far produced 3-D liver models that stay functional and stable for up to 60 days, which is an improvement from the previously established functionality of 28 days. The printed liver tissue can be used for drug testing, offering an alternative to animal and in vitro experiments. It also offers new hope to people with various genetic conditions who could benefit from a transplant. In 2016, Chinese scientists successfully printed a part of the hearts left atrium (left atrial appendage). Occlusion of this part can play a role in preventing stroke in patients with atrial fibrillation. It appears that 3-D technology can offer an improved presentation of an individuals left atrial appendage compared to conventional imaging methods. This is essential for surgeons as they need an accurate preoperative reference before they start with the occlusion procedure.

Eric Topol, the Director and Professor of Genomics at Scripps Translational Science Institute, describes the now-ubiquitous smartphones as the hub of future medicine. Mobile phones and mobile peripherals can be used as biosensorsmeasuring blood pressure, heart rhythm, blood sugar levels and even brain wavesas well as functioning as a personal scanner such as an otoscope or ultrasound. People can now perform many measurements by themselves, when they want and where it is most convenient for them. They can view and interpret their data without having to visit the doctor, making health care increasingly more personal and individual-based.

Since the dawn of personalized medicine, several limitations of this approach have been discussed. Some experts argue that it carries a risk of reducing medicine to molecular profiling. A properly executed traditional medicine practice should already include a degree of personalization by looking at your unique characteristics, medical history and social circumstances. Many social scientists and bioethicists believe that the label personalized medicine could involve a radical shift of responsibility toward the individual, potentially dismissing other socioeconomic factors that are important to examine as well. The approach might in some cases contribute to the culture of blaming the victim, creating stigmatization of certain groups of people and taking the public health resources away from initiatives that try to address the social disparities and inequity that also affect health.

An article published by the Hastings Centera research institute that addresses ethical and social issues in health care, science, and technologyhighlighted that there might be some erroneous expectations surrounding personalized medicine. It is very unlikely that in the future, you will be able to receive a unique prescription or a treatment specific to you alone. Personalized medicine is more about classifying people into groups based on genomic information and looking at your health risks and treatment responses in the context of that genetic group.

Many people are concerned that being classified as a member of a certain subgroup could, for example, increase your insurance rates or make you a less desirable job candidate. These considerations are not unfounded. Personalized medicine goes hand in hand with increased data accumulation, and data security remains a challenge. Moreover, being in a certain subgroup might oblige you to participate in screening programs as a matter of social responsibility somewhat reducing the freedom of personal choice.

There are also potential ethical implications for doctors handling genomic information. For instance, doctors might need to contemplate withdrawing some pieces of information that have no medical utility. The disclosure process would require some careful editing to prevent confusing or scaring the patient further. However, this could signal the return to paternalistic medicine where the doctor decides what is best for you and what you should be told. There is clearly a need for a solid ethical framework in this field, as well as a need for careful monitoring to ensure concerns are balanced with benefits.

Visit link:
Moving from Population Medicine to Personalized Medicine

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine | Sarah Cannon

♫ Wednesday, October 9th, 2019

Molecular profiling has emerged to play a pivotal role in personalized medicine, classifying tumors based on genetic profiles for the purposes of cancer diagnosis or treatment,or predicting response to therapy. Innovative technologies, including next generation sequencing (NGS), can now clinically identify an extensive panel of actionable and exploratory genetic alterations.

In the US, Sarah Cannon physicians identify and order the most appropriate molecular test(s) from a number of best in class commercial laboratory service providers, such as Foundation Medicine,PathGroup, or Caris Life Sciencesaccredited from the Commission on Laboratory Accreditation of the College of American Pathologists (CAP). The NGS panels that are ordered target 35 to over 400 genes that are currently known to be altered in solid tumors or blood cancers. The appropriate molecular test and/or NGS panel is chosen based on tumor characteristics.

In the UK, Sarah Cannon is working withUniversity College London - Advanced Diagnostics (UCL-AD), a CPA-accreditedmolecular profiling laboratory, to develop novel technologies and assay menus and provide a clinical service to the private sector and the NHS, as well as a comprehensive research platform to the pharmaceutical industry.

With access to thousands of patients with different tumor types and access to the latest technologies used for molecular profiling, we are able to rapidly identify eligible patients for early and late-phase clinical trials and explore novel biomarkers that predict response to specific treatments.

The rest is here:
Personalized Medicine | Sarah Cannon

♫ Posted in Personalized Medicine | | Comments Off»

RSS Feeds – ClinicalTrials.gov

♫ Wednesday, October 2nd, 2019

RSS allows you to receive information and updates from a Web site. This page explains how to set up RSS feeds that will notify you of new study information on ClinicalTrials.gov. Subscribing to an RSS feed saves you time because you will not have to check each study record in your search results for updates.

RSS feeds can provide updates to the results of a specific search, on all recently addedstudy records,or on all recently modified studies. The RSS feed will automatically list additions and updates to your search results in either your Internet browser or a feed reader (see How to Subscribe to a Feed).

Creating an RSS feed for a specific search allows you to easily access and browse study records meeting your search criteria that have been first posted or last update posted in the last 14 days. To create the feed from the Search Results page, follow the instructions provided in the example below.

To practice creating an RSS feed for a targeted search for recruiting studies about the condition Huntington Disease, follow these steps:

To read the RSS feed updates, you need a reader, also called an aggregator. Readers can be Web based (for example, Google Reader), part of your browser (for example, Microsoft Internet Explorer, Mozilla Firefox), part of your e-mail client (for example, Microsoft Outlook), or installed on your computer. Web-based and e-mail client readers let you read RSS feeds from any computer. Feed subscriptions in your browser or reader software installed on your computer will be available only on the computer used to subscribe to the feeds.

The steps below describe how to subscribe to an RSS feed using MS Internet Explorer or Mozilla Firefox. The process may be slightly different for other browsers. Refer to your browser's help files for more information.

In your browser, create or open the RSS feed that you want to subscribe to. (See the instructions for creating an RSS Feed for a Specific Search.) To create an RSS feed for all studies on ClinicalTrials.gov, do not enter any words in the search boxes, click on Search or Search all studies (depending on which page you are on).

To practice subscribing to a feed for Recruiting studies on Huntington Disease using your browser, follow these steps:

After you have subscribed, you can view the RSS feed at any time using the same browser. The title of each feed item is the title of the study record that has been added or updated. Click on the title to open the study record page on ClinicalTrials.gov.

Your feed may be empty sometimes. This happens when there are no recent additions or updates to your original search results.

To delete the feed, right-click on it in your Feeds or Bookmarks list and select Delete.

In your browser, create or open the RSS feed that you want to subscribe to. (See the instructions for creating an RSS Feed for a Specific Search.) Copy the URL of the RSS feed page open in your browser and paste it into your feed reader application or software.

The process for subscribing to a feed varies, depending on the feed reader software. The feed reader's instructions should explain how to modify the RSS feed name or delete the feed.

Instead of subscribing to an RSS feed, you can use your browser to bookmark a Search Results page or label it as a "favorite." For example, a bookmarked Search Results page for studies on anticonvulsants recruiting in Chicago would appear as "Search of: Recruiting Studies | Anticonvulsants | United States, Illinois | Chicago - List Results - ClinicalTrials.gov" in your list of bookmarks or favorites. Each time you visit the page, you will see all the current results for your search, including records that have been recently added or updated and records that have not changed.

This page last reviewed in September 2017

See the original post:
RSS Feeds - ClinicalTrials.gov

♫ Posted in Personalized Medicine | | Comments Off»

Integrative Medicine Cincinnati | Huber Personalized Medicine

♫ Tuesday, September 24th, 2019

If you read chapter one and two of this Me Time thought line then hopefully this will put a cherry on that chocolate sundae. I met this morning with a fun group to discuss the use of meditation as a tool for stress relief. In fact, we were diving much deeper into how meditation can be used to rewrite your future experience. Creating your future through your thoughts and feelings rather than playing victim to whatever your repeated past patters will predictably produce for you. We reviewed some of the work presented by Dr. Joe Dispenza who is fond of saying that our stress hormones cause us to look at our present environment with fear and trepidation turning us toward survival mode and becoming selfish. Its all about being self-centered, self-important, self-involved as we look to protect the ME.

The facade I present to the world is not really me. The real me, the guy who walks around in his underwear, unshaven

Read the original post:
Integrative Medicine Cincinnati | Huber Personalized Medicine

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine – Center for Individualized Medicine …

♫ Saturday, September 14th, 2019

Personalized Medicine

Better diagnoses, earlier interventions, more-efficient drug therapies, customized treatment plans. These are the promises of personalized medicine, also known as precision medicine or individualized medicine.

Individualized, precision or personalized medicine provides a genomic blueprint to determine each person's unique disease susceptibility, define preventive measures and enable targeted therapies to promote wellness.

Mayo Clinic has provided personalized or precision medicine to every one of its patients for nearly 150 years. But in recent years, advances in genomic and clinical science have created innovative opportunities to further tailor health care to each patient.

The Center for Individualized Medicine at Mayo Clinic is taking the practice of personalized medicine and applying it to the entire spectrum of health care using sophisticated methods of genomic sequencing and molecular analysis.

Personalized Medicine 101

Living better, living longer

Personalized Medicine Concepts

The Biomarker Discovery Program captures genetic information from cells and analyzes it, searching for genetic patterns to help physicians make more precise diagnoses and prescribe more effective, individualized treatments.

The Microbiome Program explores the genetic code of the body's microorganisms, using the latest techniques to profile an individual's microbiome to detect, prevent and diagnose infections and other diseases.

The Pharmacogenomics Program investigates how variations in genes affect response to medications, thereby using a patient's genetic profile to predict a drug's efficacy, guide dosage and improve patient safety.

Genomic sequencing is a process for analyzing a sample of DNA taken from your blood. In the lab, technicians extract DNA and prepare it for sequencing.

The Clinomics Program quickly moves discoveries from the research lab to the clinical setting, with practical, cost-efficient genomic tests for diagnosing and treating patients.

The Epigenomics Program investigates the role of the epigenome, examines which factors act on individual genes, and how certain changes in the epigenome affect our health.

The Center for Individualized Medicine is a strategic priority for the Campaign for Mayo Clinic.

.

See the original post:
Personalized Medicine - Center for Individualized Medicine ...

♫ Posted in Personalized Medicine | | Comments Off»

Consumer Awareness of Personalized Medicine Has Only Grown by …

♫ Wednesday, May 8th, 2019

Consumer awareness of personalized medicine is up 4% from 2018, according to a new report from Dosis, an AI-powered personalized dosing platform. The 2019 Dosis Personalized and Digital Medicine Consumer Report surveyed more than 1,000 consumers, weighted for the U.S. population, to gain a better understanding of how big the disconnect is between the advances in personalized medicine approaches and general consumer awareness of its benefits.

Consumer Awareness of Personalized Medicine Continues to be Slow

While the report found consumer awareness of personalized medicine has risen to 33% in 2019 from 29% in 2018, the progress with educating patients on the improvements in care that it can bring, along with the treatments associated with its practice, continues to be slow. In fact, consumer awareness has only grown by around 1% year-over-year since 2013.

Somewhat surprisingly, those 65+ were the most likely (37%) to be familiar with personalized medicine. Its often believed that elderly patients are reluctant to try new technologies or innovative alternatives to traditional medicine, but its also true that they are the age group most likely to be dealing with some type of healthcare issue.

Additionally, the earliest uses of personalized medicine have been in oncology, and one-quarter of new cancer cases are diagnosed in people aged 65 to 74. As these older patients are spending more time within care facilities and with their primary care provider than younger adults, its likely that theyve become more familiar with the potential for medicine personalized to address unique health ailments.

Familiarity with Personalized Medicine Increases Patient Interest in It

To find out if unfamiliarity with personalized medicine leads to less interest in using it as a treatment option, we provided respondents with this definition of personalized medicine after their initial familiarity responses: A medical treatment determined to be best for you based on your unique predicted response or risk of disease.

Respondents were asked if they would be interested in personalized medicine options defined in this way. Of the subset of consumers that previously noted they had familiarity with personalized medicine, nearly half (49%) said they were interested in personalized medicine under this definition. Comparatively, of those that said they were previously unaware of personalized medicine only 22% noted they would be interested in personalized medicine with this definition.

Patients Need to Be Educated on Personalized Medicine

Clearly, simply defining personalized medicine is not enough to get consumers to jump on the idea of using it for their future treatments. This is just further proof that patients need to be educated on personalized medicine, as well as the broader notion that they are different in their own way from any other patient over a period of time. Many consumers will still need to be walked through how their unique complement of genes, lifestyle and environmental factors should be considered when creating the best treatment plan for them.

Other key findings from the report include:

60% of those tracking data willing to share it with their healthcare provider to improve their health; however, only 14% said they would be willing to share their data with a provider to specifically influence personalized treatment.

Generation Z (18-24-year-olds) were the most likely (17%) to say they would be willing to share their tracked data with their providers to gain access to more personalized treatments.

Respondents wereasked consumers if they have taken a direct-to-consumer DNA or Gene Test with the specific goal of sharing with their provider to inform their treatment plan. Nearly 6% of consumers indicated that they took a test with that direct aim in mind, meaning that may be a top driver of interest in taking these at-home test.

Only 24% of consumers said they would be willing to take a diagnostic test for access to personalized medicine treatments.

So would consumers opt for a personalized treatment outside their insurance coverage if they were confronted with a serious condition? 32% of consumers said they would seek personalized medicine alternatives for a serious condition, but there are financial limits. Nearly two-thirds of that 32% said they would stop pursuing personalized medicine alternatives for a serious condition if treatments were priced more than their annual deductible.

Impact of Findings

As more consumers are educated on how their genetic makeup, lifestyle and environmental factors uniquely affect their medical treatments, I believe both awareness of and interest in personalized medicine will continue to grow, said Shivrat Chhabra, Founder & CEO of Dosis. Younger patients have expressed growing dissatisfaction with traditional care, and the findings of our report indicate that their interest in technology may be a major opportunity to further their awareness in personalized medicine alternatives.

See the article here:
Consumer Awareness of Personalized Medicine Has Only Grown by ...

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine Conferences 2019 | New Zealand 2019 …

♫ Sunday, April 14th, 2019

Sessions/Tracks

Track 1: Precision Medicine

The concept of precision medicine, in which health care is individually customized on the basis of a person's genes, lifestyle and environment. Transfusion patients have been matched with donors according to blood type for more than a century. But advances in genetics, and the growing availability of health data, present an opportunity to make precise personalized patient care a clinical reality.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 2: Precision Medicine and Novel Technology

Precision medicine aims to provide the right treatment for the right patient at the right time with treatment directed on the basis of the targetable tumoral aberrations rather than just a traditional histologic subtype. However to facilitate this approach, clinicians require patient derived samples. Prostate cancer is challenging to culturein vitro. Recent development of novel organoidin vitroculture technology has led to the development of multiple newin vitroprostate cancer cell line models. We aim to apply organoid culture technology to develop novelin vitroprostate cancer cell line models and propagate patient derived samples to allow drug testing and next generation sequencing as part of a precision medicine approach to early recurrent prostate cancer.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 3: Future of personalized medicine

Personalized Medicine Meetingis to develop a routine of medication that uses an individual's hereditary profile to guide choices made with respect to the counteractive action, determination, and treatment of the ailment. Information of a patient's hereditary profile can offer specialists some assistance with selecting the best possible prescription or treatment and manage it utilizing the correct measurement or regimen. Utilized for the treatment as Personalized growth solution, Diabetes-related sickness: hazard appraisal and administration, Personalized pharmaceutical: New procedures and monetary ramifications, Implications of customized prescription in the treatment of HIV, Applications of a customized drug in uncommon illnesses, Translational Medicine.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 4: Individualized Treatment through Personalized Medicine

Personalised medicine turns this approach on its head. It recognizes that complex diseases should no longer be considered as a single entity. One disease may have many different forms, or subtypes, resulting from the complex interaction of our biological make-up and the diverse pathological and physiological processes in our bodies. These will not only vary between patients who have the same disease but also within an individual patient as they get older and their body changes. As we integrate and analyses genomic and other data, we can find common factors and causes of variation, resulting in the discovery of new pathways of disease, changing how diseases are thought of and treated. It enables us to recognize that the same underlying change in our DNA or genome can lead to problems in very different parts of the body, which would not have been previously identified with a more traditional care approach.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 5: Precision Pathology

The role of predictive pathology or the accurate assessment of morphology at the microscopic level. In breast cancer, this has been most useful where histologic attributes such as the classification of tubular and cribriform carcinoma dictates surgery while neoadjuvant studies suggest that patients with lobular carcinoma are not likely to benefit from chemotherapy. The next level of 'personalized pathology' at the tissue-cellular level is the use of 'protein biomarker panels' to classify the disease process and ultimately drive tumor characterization and treatment. Precision pathology will focus on the evolution of predictive pathology from a subjective, 'opinion-based' approach to a quantitative science. The individual components of the precise pathology platform including advanced image analysis, biomarker quantitation with mathematical modeling and the integration with fluid-based (i.e. blood, urine) analytics as drivers of next generation precise patient phenotyping.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 6: Predictive Biomarkers

In drug, abiomarkerand sub-nuclear markers is the quantifiable pointer of the reality or region of some disease state. All the more overall itis anything that can be used as a marker of a particular illness state or some other physiological state of a living being Medication Symptomatic Co-Improvement. In the present time of stratified arrangement andbiomarker-driven medications, the inside has moved from figures considering the customary anatomic orchestrating systems to coordinate the choice of treatment for an individual patient to a planned strategy using the inherited beautifiers of the tumor and the genotype of the patient.Genomicsand different developments have, all things considered, Personalized Medicine Congress 2018 added to the unmistakable verification and the change ofbiomarkers, for example, Stratification biomarkers in modified pharmaceutical.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 7: Precision Medicine: Oncology

Precision Medicine in Oncology is doled out to illuminating, instructing, and encouraging the trading of clinically pertinent data with respect to the disclosure and utilization of new Drug regimens, Molecular biomarkers, Cancer genomics, Molecular growth and Diagnostics in strong tumors and hematologic malignancies, and in addition their effect on oncology watch over patients. Over late decades Cancer investigate has found an incredible and personalized medication to tumor research and treatment.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 8: Data science to advance precision medicine

Healthcare and medical research are generating more and more complex data, encompassing clinical investigations, genomic medicine, imaging, pharmacokinetics, metabolomics, epidemiology and beyond. This Data Science can form the basis for precision medicine, approaching disease prevention and treatment by taking into account individual variability in genes, environment, and lifestyle. By deeply profiling individual patients and using this to improve predictive models of pathology in individual patients, advances will be made in elucidating of the drivers of the disease and making precise targeted treatments, providing the right treatment to the right patient at the right time. Both biologists and clinicians need to understand this emerging and highly translational approach.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 9: Preventive Medicines

Preventive Medicine is sharpened by all specialists to keep their patients sound. It is also an extraordinary therapeutic distinguishing strength saw by the American Board of Medical Specialties (ABMS). Preventive Medicine focuses on the prosperity of individuals, gatherings, and portrayed peoples. It is similarly used for the treatment for strength, visual hindrance. The Epidemiology Division applies inquire about systems to fathom the illustrations and explanations behind prosperity and affliction in the people and to make a translation of this learning into ventures proposed to turn away disease. The division has a long history of consideration in NIH-bolstered multi-site, longitudinal accomplice studies, and its staff deal with various pro began, NIH-upheld investigation endeavors and trials. Open trust in antibodies is a key to the accomplishment of immunization ventures worldwide in the time of preventive solution.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 10: Cardiovascular medicine

The goal of the Personalized Medicine in cardiac research is to stimulate understanding of promising new essential examination disclosures for the treatment of heart disillusionment and arrhythmias through especially formed clinical trials that display suitability and security. Vascular Medicine encompasses an extensive variety of various sickness states. As the field of vascular Medicine builds up, the degree of ailments being managed changes. Cardiovascular revamping suggests the changes in estimate, shape, structure and physiology of the heart after harm to the myocardium. The mischief is regularly a direct result of extraordinary myocardial dead tissue. To depict the development in lipoprotein translation by hypothyroidism, adipocytes were prepared from control and hypothyroid rats. While LPL mix was higher in hypothyroid adipocytes, with no modification in mRNA levels, there was no extension in hormone-delicate lipase (HSL) mix.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 11: Precision Immunotherapy

Immunotherapy is a type of treatment that helps the bodys immune system fight cancer. Several kinds of immunotherapy, including immune checkpoint inhibitors, adoptive cell transfer, and therapeutic vaccines are either commercially available or in clinical development. To date, six immune checkpoint inhibitors have been approved by FDA for the treatment of eight types of cancer. One of the inhibitors has also been approved to treat any solid tumor that has a specific genetic feature. This was the first FDA approval of its kind and a major advance for precision cancer medicine, in which the molecular characteristics of a tumor are used to identify effective therapies.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 12: Pharmacogenomics & Personalized Medicine

Pharmacogenomics is a control in innate qualities that applies Recombinant DNA, DNA sequencing strategies, and bioinformatics to gathering, store up, and separate the limit and structure of genomes. Drives in genomics have set off an insurrection in exposure based examination to see even the most complex natural systems, for instance, the psyche. The field fuses attempts to choose the entire DNA gathering and human genome variety of living things and fine-scale inherited mapping. The field furthermore consolidates examinations of intragenomic wonders, for instance, heterosis, epistasis, pleiotropic and distinctive relationship amidst loci and all inside the genome and met genomics. Close genomics is an invigorating new field of regular investigation in which the genome groupings of different species human, mouse and a wide variety of various life frames from yeast to chimpanzees are contemplated.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 13: Approaches to Stem Cells and Cell therapy

Personalized Medicine can be used to discover around a man's genetic beauty care products and to unravel the study of their tumor. Using this information, experts need to perceive reckoning, screening, and treatment procedures that may be more fruitful and cause less indication than would be ordinary with standard drugs. By performing more innate tests and examination, authorities may adjust treatment to each patient's needs. Making a tweaked harm screening and treatment game plan consolidates: Determining the chances that a man will make development and choosing screening methods to cut down the threat, Matching patients with meds that will presumably be convincing and cause less responses, Predicting the risk of rehash (return of Cancer).

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 14: Biospecimens as building blocks for Precision Medicine

Biospecimens contain molecules that can be analyzed for indications of diseases. Biospecimens may confirm whether a disease is present or absent in a particular person, and research on biospecimens is especially helpful for understanding more about how disease processes may start and progress. This understanding may lead to better detection of diseases at the earliest stages and may permit design of more effective treatments. Annotated human biospecimens are critical building blocks for precision medicine discovery and essential to the preclinical validation of resulting hypotheses. In this session, learn how advances in technology are improving access to a diverse range of biospecimens from patient populations and yielding increasingly useful amounts of information upon analysis.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 15: Personalized Modeling of Precision Health

Personalized Medicine is a creating routine of remedy that uses a person's inherited profile to direct decisions made as for the balancing activity, investigation, and treatment of ailment. Learning of a patient's innate profile can offer experts some help with choosing the right solution or treatment and control it using the most ideal estimations or regimen. Used for the treatment as Personalized harm pharmaceutical, Diabetes-related disorder: danger assessment and organization, Personalized medication: New strategies and fiscal repercussions, Implications of altered solution in treatment of HIV, Applications of modified remedy in exceptional contaminations, Translational Medicine.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 16: Personalized Health Care Delivery

Personalized drug is a field of prescription that includes anticipating the probability of disease and building up preventive measures remembering the true objective to either keep the infirmity all things considered or out and out reduction its impact upon the patient, (for instance, by maintaining a strategic distance from mortality or compelling grimness). Strategies and measures join New-conceived screening, diagnostic testing, Medical bioinformatics, Prenatal testing, Carrier testing, Preconception testing. Newborn child screening is a general prosperity program expected to screen babies not long after origination for a summary of conditions that are treatable, however not clinically clear in the baby time frame. Pre-birth testing: Prenatal testing is used to look for disorders and conditions in a hatchling or creating life before it is imagined. This sort of testing is offered for couples who have an extended peril of having a youngster with an innate or chromosomal issue. Screening can choose the sex of the incipient organism. Pre-birth testing can offer a couple some help with choosing whether to rashly end the pregnancy. Like symptomatic testing, pre-birth testing can be non-obtrusive or meddlesome. Non-prominent techniques fuse examinations of the woman's womb through ultrasonography or maternal serum screens. These non-nosy methodology can evaluate risk of a condition, however can't choose with conviction if the developing life has a condition.

9th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Oct 26-27, 2018 Boston, Massachusetts, USA; 10th European Conference on Predictive, Preventive & Personalized Medicine and Molecular Diagnostics August 29-30, 2019 London, UK; 15th International Conference and Exhibition on Metabolomics & Systems Biology April 29-30, 2019 Kyoto, Japan; 12th International Conference on Genomics and Molecular Biology April 15-17, 2019 Berlin, Germany; 10th Annual Congress on Biomarkers, Clinical Research & Therapeutics October 03-04, 2018 Los Angeles, California, USA; 2nd World Congress on Cell and Structural Biology March 20-21, 2019 Sydney, Australia; Annual Congress on Medicine November 05-06, 2018 Bangkok, Thailand; International Conference on Clinical Case Reports April 04-06, 2019 Paris, France

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association(PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 17: Treatment of Genetic Disorders

Gene therapy is hoped to cure or improve treatment of genetic disorders by replacing the mutated or malfunctioned gene, manipulating or turning off the gene causing the disease or stimulate other bodily functions to fight the disease. The most common method is replacement of a malfunctioned or sometimes a missed gene with a healthy one. However, gene therapy poses a risk of potentially serious complications, in the first place due to the method that is used to insert the new genes the use of viruses. These have the ability to identify certain cells as well as to transmit the genetic material into the cells containing malfunctioned or missed gene. For that reason modified viruses are used as vectors or carriers of the healthy genes. This method of insertion of healthy genes may not seem problematic at a first glance but it can cause cause potentially serious complications as already mentioned earlier.

♫ Posted in Personalized Medicine | | Comments Off»

Precision medicine and pharmacogenomics – Mayo Clinic

♫ Monday, April 1st, 2019

Precision medicine and pharmacogenomics

Personalized medicine holds the promise that treatments will one day be tailored to your genetic makeup.

Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.

Your age, lifestyle and health all influence your response to medications. But so do your genes. Pharmacogenomics is the study of how a person's unique genetic makeup (genome) influences his or her response to medications.

Precision medicine aims to customize health care, with decisions and treatments tailored to each individual in every way possible. Pharmacogenomics is part of precision medicine.

Although genomic testing is still a relatively new development in drug treatment, this field is rapidly expanding. Currently, more than 200 drugs have label information regarding pharmacogenomic biomarkers some measurable or identifiable genetic information that can be used to individualize the use of a drug.

Each gene provides the blueprint for the production of a certain protein in the body. A particular protein may have an important role in drug treatment for one of several reasons, including the following:

When researchers compare the genomes of people taking the same drug, they may discover that a set of people who share a certain genetic variation also share a common treatment response, such as:

This kind of treatment information is currently used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.

In cancer treatments, there are two genomes that may influence prescribing decisions the genome of the person with cancer (the germline genome) and the genome of the cancerous (malignant) tumor (the somatic genome).

There are many causes of cancer, but most cancers are associated with damaged DNA that allows cells to grow unchecked. The "incorrect" genetic material of the unchecked growth the malignant tumor is really a separate genome that may provide clues for treatment.

One example is thiopurine methyltransferase (TPMT) testing for people who are candidates for thiopurine drug therapy. Thiopurine drugs are used to treat some autoimmune disorders, including Crohn's disease and rheumatoid arthritis, as well as some types of cancer, such as childhood leukemia.

The TPMT enzyme helps break down thiopurine drugs. People who are TPMT deficient don't break down and clear out these drugs quickly enough. As a result, the drug concentration in the body is too high and increases the risk of side effects, such as damage to the bone marrow (hematopoietic toxicity).

Genetic testing can identify people with TPMT deficiency so that their doctors can take steps to reduce the risk of serious side effects by prescribing lower than usual doses of thiopurine drugs or by using other drugs instead.

Although pharmacogenomics has great promise and has made important strides in recent years, it's still in its early stages. Clinical trials are needed not only to identify links between genes and treatment outcomes but also to confirm initial findings, clarify the meaning of these associations and translate them into prescribing guidelines.

Nonetheless, progress in this field points toward a time when pharmacogenomics will be part of routine medical care at least for some drugs.

.

Go here to read the rest:
Precision medicine and pharmacogenomics - Mayo Clinic

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Wellness | Internal Medicine

♫ Tuesday, March 19th, 2019

If you believe that prevention is the best cure, then youve come to the right place. Welcome to Personalized Wellness Internal Medicine.

Even prior to the opening of our new state-ofthe-art Hoffman Estates office in 2013, we have been dedicated to a patient-centered approach to medical care. By combining the best of traditional Internal medicine and complementary integrative medicine, Dr. Mary George helps her patients transition from disease care to optimal health and wellness true healthcare. With the affiliation with MDVIP (as of August 2018), a national leader in wellness and prevention, this vision has become a true reality.

With a strong focus on preventive care and wellness, Personalized Wellness Internal Medicine offers unique treatment options for unique health challenges in people of all ages. Dr. George offers personal, one-on-one care with a bedside manner that makes patients feel welcome and comfortable. She gives you the time you need to express any health concerns. She attentively listens and takes as much time as necessary to provide thorough consultation, diagnosis, and treatment. Dr. George will take the time to answer all your questions. Educating and empowering the patient allows each individual to pursue, achieve and maintain optimal health and wellness.

♫ Posted in Personalized Medicine | | Comments Off»

Division of Biomedical Informatics and Personalized …

♫ Tuesday, March 19th, 2019

Bioinformatics implies a multidisciplinary field that seeks to analyze and manage vast quantities of biological, molecular and genetic data through computer technology. Personalized Medicine is an emerging field that uses an individuals genetic profile to aid in the diagnosis, prevention, and treatment of diseases.

Created in 2015 and led by Dr. Kathleen Barnes, the Colorado Center for Personalized Medicines (CCPM) mission is to integrate bioinformatics and personalized medicine using patient health record information and big data with genetic information to develop personally tailored treatments and cures for different illnesses and diseases. This will be done by combining cutting edge biomedical technology with large-scale computing and the latest in genetic sequencing technology.

Kathleen Barnes: This Is What People Are Talking About When They Say Big Data.

Discoveries like these have the potential to improve treatment for complex diseases, as well as to help identify and screen high-risk populations. But personalized medicine also aims higher, at understanding how and why genes cause disease and why, sometimes, they don't.

Read the original:
Division of Biomedical Informatics and Personalized ...

♫ Posted in Personalized Medicine | | Comments Off»

Pharmacogenomics and Personalized Medicine – Dove Press

♫ Monday, March 18th, 2019

- 183 records -

Original Research

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Caldern-Ospina CA, Pea N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

Original Research

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Original Research

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

Review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Original Research

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

Original Research

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Original Research

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Review

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Here is the original post:
Pharmacogenomics and Personalized Medicine - Dove Press

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine in Oncology: Global Partnering Terms …

♫ Sunday, March 17th, 2019

DUBLIN--(BUSINESS WIRE)--The "Global Personalized Medicine in Oncology Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the world's leading companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Chapters

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2014. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report Scope

This report is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

The report includes:

In this report, the available contracts are listed by:

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

For more information about this report visit https://www.researchandmarkets.com/research/jhhqcn/personalized?w=4

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine for Brain Tumors | Cleveland Clinic

♫ Thursday, March 14th, 2019

What is Personalized Medicine?

Genes are part of our DNA, or genetic blueprint. Personalized medicine is a way to gather information about the unique genetic makeup of your brain tumor that can help you and your physician decide on the best treatment plan for you.

Personalized medicine makes a more targeted approach to treatment possible. It provides data about sensitivities or resistance your tumor may have. It can determine how likely you are to respond to certain medicines, steering your doctor toward the safest, most effective choice whether an FDA-approved drug or one only available in a leading-edge clinical trial.

Personalized medicine is a simple, painless process. It involves taking only a small amount of tissue through a biopsy, which is sent for an analysis of the hundreds of known cancer genes. The results are available in two to three weeks. Your Cleveland Clinic physician will call you to discuss the findings and what they mean for your course of treatment.

Personalized medicine is extremely sensitive in finding all types of changes in genes, with no false positives. More than two-thirds of the changes it detects would not be able to be found by any other kind of testing. However, there is no guarantee that the testing will generate results that will be useful in guiding your therapy.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Continued here:
Personalized Medicine for Brain Tumors | Cleveland Clinic

♫ Posted in Personalized Medicine | | Comments Off»

Personalized Medicine – Coriell Personalized Medicine …

♫ Thursday, March 14th, 2019

Our health is determined by many factors, among them: the genetics we inherit; our race, age and gender; our lifestyle; and our socioeconomic environment. These factors differ for everyone and change over our lifespan. Also unique to everyone is their experience with disease and how they respond to prescription drugs or other medical therapies.

Personalized medicine is the use of genomic information in addition to family history, lifestyle, and environmental factors to customize health management. By combining genomic and clinical information, more accurate predictions can be made about a person's susceptibility of developing disease, the course of disease, and response to treatment.

When your genetic information informs your increased risk for a disease and you make lifestyle changes to reduce that risk, personalized medicine has revealed itself. If you have a gene variation that influences how you process a medication and your physician prescribes dosing instructions accordingly, your medical care is now safer, well-timed, accurate, and more cost-effective for you and our healthcare system.

Personalized medicine has the potential to offer patients and their doctors several advantages, including:

Personalized medicine is a relatively new field, and outcomes research and evidence-based literature is important to its integration into healthcare delivery. The Coriell Personalized Medicine Collaborative(CPMC) research study is contributing to both: CPMCstudy participants regularly complete follow-up questionnaires that explore how they are using the information they receive from the study, whether they are making lifestyle changes to reduce their disease risk or improving their medication response, and if they are sharing their results with family and healthcare providers. Additionally, Coriell has and will continue to publish scientific findings from the CPMCstudy, contributing to new medical literature.

Here on the Coriell research study website you will learn more about the utility of personalized medicine in clinical care, how physicians can prescribe medications that will be more efficient for you, and how the CPMCstudy is reporting many health conditions and drug responses to study participants.

For more information about personalized medicine, visit the follow sites:

The human body is composed of trillions of cells cells being the building blocks of all living things. [ Learn More ]

Pharmacogenomics is the study of genetic variation and medication response. [ Learn More ]

Learn how genetic information can be used in clinical decision-making and preventive care. [ Learn More ]

Continue reading here:
Personalized Medicine - Coriell Personalized Medicine ...

♫ Posted in Personalized Medicine | | Comments Off»

What is the difference between precision medicine and …

♫ Thursday, March 14th, 2019

There is a lot of overlap between the terms "precision medicine" and "personalized medicine." According to the National Research Council, "personalized medicine" is an older term with a meaning similar to "precision medicine." However, there was concern that the word "personalized" could be misinterpreted to imply that treatments and preventions are being developed uniquely for each individual; in precision medicine, the focus is on identifying which approaches will be effective for which patients based on genetic, environmental, and lifestyle factors. The Council therefore preferred the term "precision medicine" to "personalized medicine." However, some people still use the two terms interchangeably.

Pharmacogenomics is a part of precision medicine. Pharmacogenomics is the study of how genes affect a persons response to particular drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that are tailored to variations in a persons genes.

Read the rest here:
What is the difference between precision medicine and ...

♫ Posted in Personalized Medicine | | Comments Off»

What is Personalized Medicine | Abbott Companion Diagnostics

♫ Tuesday, February 12th, 2019

Personalized Medicine is defined as the customization of healthcare, where medical decisions are tailored to the individual patient based on their susceptibility to disease or response to a particular treatment. A key component of personalized medicine includes advanced testing of a patient's genetic information to help identify targeted treatment options.The practice of personalized medicine is based on the premise that for many diseases, including cancer, there is no one-size-fits-all treatment. In personalized medicine, diagnostic tests are used to help tailor disease prevention, diagnosis, and treatment based on the genetic makeup of a particular patient.1

At Abbott Molecular, we know that when patients and physicians are informed about the diagnostic and treatment opportunities offered by the promise of personalized medicine, lives can be saved. VisitRichard's Storyto learn about how personalized medicine has provided options and hope to patients and their families.

Companion Diagnostics (CDx) are laboratory tests developed in parallel with particular drugs to identify patients who are most likely to benefit from treatment with these drugs. Information from test results helps physicians to personalize patient treatment plans. Generally speaking, the practice of personalized medicine has been described as providing the right patient with the right drug at the right dose at the right time."1According to the Food and Drug Administration, personalized medicine may be considered as customizing medical treatment to the individual characteristics, needs, and preferences of a patient during all stages of care, including prevention, diagnosis, treatment, and follow-up.2

Many of the world's leading pharmaceutical, biological, and entrepreneurial companies select Abbott Molecular as their companion to develop comprehensive, companion diagnostic products and strategies.

There is no typical cancer patient. People diagnosed with cancer represent various races, ages, and lifestyles. Working with your physician to understand the causes, diagnosis, and treatment of cancer may help minimize concerns and is a positive first step in any fight against the disease. The following categories of frequently asked questions are provided for educational purposes only and are not intended to replace discussions with your healthcare provider.

1, 2http://www.fda.gov/ScienceResearch/SpecialTopics/PersonalizedMedicine/ucm20041021.htm. Accessed 3.25.14.

♫ Posted in Personalized Medicine | | Comments Off»

Selected topics in genetics & personalized medicine …

♫ Tuesday, February 12th, 2019

Genetic testing

TheHuman Genome Projectled to the discovery of thousands of disease genes. Genetic testing can help patients determine disease risk and the likelihood of passing on or inheriting certain disorders.

Learn more aboutgenetic testingand how to use this information in your practice.

LINKS 1-6: Topics in genetics & personalized medicine

Genetic testing is expected to become a routine part of patient care in the future, but unless this DNA information is protected, the potential grows for discrimination against people based on their genetic information.

Understand more aboutgenetic discrimination.

LINKS 1-6: Topics in genetics & personalized medicine

Gene patentingis a broad term referring to the patenting of genetic sequences such as DNA and RNA, and to alternative forms of DNA such as cDNA (complementary DNA).

Learn more aboutgene patentingand its impact on patient care.

LINKS 1-6: Topics in genetics & personalized medicine

Direct-to-Consumer (DTC) genetic tests are marketed and sold directly to consumers, and do not require the assistance of a physician or other health care provider to obtain or interpret.

Learn aboutDTC genetic tests.

LINKS 1-6: Topics in genetics & personalized medicine

Precision medicine is a tailored approach to health care that accounts for the individual variability in the genes, environment and lifestyle of each person.

Learn more aboutprecision medicineand the President's Precision Medicine Initiative.

LINKS 1-6: Topics in genetics & personalized medicine

Go here to read the rest:
Selected topics in genetics & personalized medicine ...

♫ Posted in Personalized Medicine | | Comments Off»

SCGPM | Stanford Center for Genomics and Personalized …

♫ Tuesday, February 12th, 2019

Cancer Genomes

Cancer is a genetic disease. It starts with one unlucky cell that loses control over growth and division and evades the immune system; it continues with accumulation of mutations in the genome of its progeny that make them grow even faster; and it eventually reaches the point where it is detected by a physician. SCGPM researchers are devising new approaches to study genomic changes in cancers, to understand cancer origins and progression, and to determine which altered genes might be developed into drug targets.

The human brain has 100 billion neurons that govern how we think, feel, learn, and remember. Defects in the formation of these neurons during development can lead to mental retardation, and during aging or in diseases such as Alzheimer's, there is a decline in cognitive function, particularly memory. SCGPM scientists are identifying the molecular changes that occur in brain cells during development, aging, and diseases. Identifying these molecular changes will provide new avenues to ameliorate neurological diseases and to prevent age-dependent decline in cognitive function.

SCGPM scientists are investigating the genetic basis of Mendelian, oligogenic, and complex human cardiovascular diseases employing high-throughput sequencing of informative families and association-based whole genome scanning methodologies with large case-control cohorts. Causal genetic variation identified through these approaches is under investigation to elucidate the mechanistic basis for the disease associations.

See the article here:
SCGPM | Stanford Center for Genomics and Personalized ...

♫ Posted in Personalized Medicine | | Comments Off»

StemCell Therapy

Archive for the ‘Personalized Medicine’ Category

NHS England Personalised medicine

Personalized Medicine Market Size & Forecast | Industry …

Moving from Population Medicine to Personalized Medicine

Personalized Medicine | Sarah Cannon

RSS Feeds – ClinicalTrials.gov

Integrative Medicine Cincinnati | Huber Personalized Medicine

Personalized Medicine – Center for Individualized Medicine …

Consumer Awareness of Personalized Medicine Has Only Grown by …

Personalized Medicine Conferences 2019 | New Zealand 2019 …

Precision medicine and pharmacogenomics – Mayo Clinic

Personalized Wellness | Internal Medicine

Division of Biomedical Informatics and Personalized …

Pharmacogenomics and Personalized Medicine – Dove Press

Personalized Medicine in Oncology: Global Partnering Terms …

Personalized Medicine for Brain Tumors | Cleveland Clinic

Personalized Medicine – Coriell Personalized Medicine …

What is the difference between precision medicine and …

What is Personalized Medicine | Abbott Companion Diagnostics

Selected topics in genetics & personalized medicine …

SCGPM | Stanford Center for Genomics and Personalized …

Categories

Archives

Recommended Sites

Recent Posts